Relay Therapeutics· @Relay_Tx · X·· 26 天前AI 评分30
AI 导读
Relay Therapeutics 在 #PeDRA2026 以壁报展示 zovegalisib 治疗 PIK3CA 驱动血管畸形的成人及青少年患者初步结果。zovegalisib 是突变选择性 PI3Kα 抑制剂。会议讨论强调该患者群体亟需推进靶向治疗选择。
正文 · 原文
Last weekend, the Relay Tx vascular anomalies team was in Virginia for #PeDRA2026! We were proud to present a poster on preliminary results of zovegalisib, a mutant-selective PI3Kα inhibitor, in adult and adolescent patients with PIK3CA-driven vascular malformations. Conversations throughout the conference continued to emphasize the urgency of advancing targeted options for this patient population, and we’re grateful to the PeDRA community for the opportunity to share our work and connect with others working to move this field forward.
来源:Relay Therapeutics · x.com